John Duplantier, MD
Allergy & Immunology · Greenwood, INNPI 1134121569
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,345 of the $5,639 with a category attached, or 77.0%. Genentech USA, Inc. accounts for 87.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $3,570 and has fallen 96.1% since, to $139 in 2025.
Across 31 payments — averaging $181.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- GSK$143
- Takeda Pharmaceuticals U.S.A., Inc.$138
- Biocryst US Sales Co., LLC$82
- Grifols USA, LLC$81
- Novartis$70
- plus $208 from 7 others
What the payments were for
- Consulting fees$4,34577%
- Travel & lodging$3937%
- Food & beverage$87516%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $4,916 |
| GSK | 5 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Biocryst US Sales Co., LLC | 2 | $82 |
| Grifols USA, LLC | 1 | $81 |
| Novartis | 3 | $70 |
| Galderma Laboratories, L.p. | 1 | $68 |
| AstraZeneca | 2 | $38 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Octapharma USA, Inc. | 1 | $24 |
| Bio Products Laboratory USA, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$4,916
How this compares
$5,639 in reported general payments places this provider in the 55th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 26 | $102,048 |
| Dupixent PenDupilumab | 25 | $94,809 |
| Dupixent SyringeDupilumab | 19 | $69,753 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $49,233 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $37,596 |
| Spiriva RespimatTiotropium Bromide | 28 | $28,554 |
| Spiriva HandihalerTiotropium Bromide | 19 | $16,567 |
| Arnuity ElliptaFluticasone Furoate | 34 | $14,359 |
| Epinephrine | 88 | $13,398 |
| Azelastine Hcl | 258 | $10,856 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,984 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $7,528 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,629 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $5,113 |
| Ipratropium Bromide | 65 | $3,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Breo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $143 | $203,236189 claims |
| AstraZenecaSymbicort | $38 | $9,98421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Greenwood
- Mitchell SmithGreenwood$33K
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
- Ketan ShethLafayette$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.